Home / Deep Research / Urea Cycle Disorder

Urea Cycle Disorder

Disease Pathophysiology Research Template

2026-02-17
Falcon MONDO:0004739 Model: Edison Scientific Literature 44 citations

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Urea Cycle Disorder
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Urea Cycle Disorder. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Pathophysiology Research Report — Urea Cycle Disorders (UCDs) (Genetic)

Scope and disease definition

Urea cycle disorders (UCDs) are inborn errors of metabolism caused by deficiency of one of the urea-cycle enzymes or associated transporters, impairing hepatic ureagenesis and leading to accumulation of neurotoxic ammonia (hyperammonemia). The urea cycle is described as “the main pathway for ammonia detoxification,” localized to “periportal hepatocytes,” and canonical UCD genes include NAGS, CPS1, OTC, ASS1, ASL, ARG1, SLC25A15 (HHH syndrome), SLC25A13 (citrin deficiency) (yin2024asurvivalguide pages 16-19). Contemporary gene-therapy reviews similarly frame UCDs as liver-centered diseases with a “permanent risk of hyperammonaemic decompensation” and neurological sequelae/death without rapid treatment; conventional therapy reduces but does not eliminate decompensation risk, and liver transplantation remains the only curative therapy (Duff et al., Apr 2024; https://doi.org/10.1002/jimd.12609) (duff2024genetherapyfor pages 1-2).

MONDO ID: Not available in retrieved evidence.

1. Core pathophysiology (molecular/cellular mechanisms)

1.1 Primary mechanism: failure of hepatic ureagenesis → hyperammonemia

Ammonia is a byproduct of protein metabolism and is definitively eliminated by hepatic urea synthesis; the urea cycle’s high-capacity “workhorse” function is required to prevent systemic ammonia accumulation (yin2024asurvivalguide pages 16-19). When urea-cycle flux is impaired by enzymatic/transporter defects, ammonia rises and alternative “first-line ammonia scavenging” via amino-acid/glutamine synthesis has limited capacity compared with ureagenesis (concept discussed in broader hyperammonemia/urea-synthesis literature) (yin2024asurvivalguide pages 16-19).

Key biochemical patterns by defect (examples): - Proximal (mitochondrial) defects (CPS1, OTC, NAGS): hyperammonemia with low citrulline/arginine and high glutamine; OTC classically shows elevated urinary orotic acid due to carbamoyl phosphate diversion to pyrimidine synthesis (fenves2025gastricbypassassociated pages 12-15, fenves2025gastricbypassassociated pages 10-12, erdal2025aminoacidmetabolism pages 4-4). - Distal (cytosolic) defects (ASS1, ASL, ARG1): accumulation of pathway intermediates (e.g., citrulline in ASS1; argininosuccinate in ASL; arginine/guanidino compounds in ARG1), with variable hyperammonemia (nteli2024argininemiapathophysiologyand pages 2-3, enokizono2023neuroimagingfindingsof pages 4-6).

1.2 Brain pathophysiology of hyperammonemia (central mechanism of morbidity)

A key, repeatedly supported concept in UCD neurotoxicity is that ammonia crosses the blood–brain barrier and is detoxified primarily in astrocytes by conversion to glutamine. In UCD-related crises, glutamine becomes an osmolyte that drives astrocytic swelling and cerebral edema.

Direct UCD-specific mechanistic statements (2023–2024): - Neuroimaging review: ammonia “diffuses freely across the blood–brain barrier” and is converted to glutamine, “which is osmotically active,” leading to astrocytic swelling and cytotoxic cerebral edema; ^1H-MRS shows increased Glx and decreased myo-inositol (an osmotic buffer) proportional to severity (Enokizono et al., Feb 2023; https://doi.org/10.1007/s11604-023-01396-0) (enokizono2023neuroimagingfindingsof pages 4-6). - UCD seizure cohort: ammonia is metabolized to glutamine in brain; glutamine accumulation increases osmolarity “leading to cerebral edema.” The authors enumerate mechanistic contributors to seizures during hyperammonemia, including “excitotoxicity,” altered aquaporin-4, “disrupted energy/glucose metabolism,” and “impaired nitric oxide synthesis” (Chanvanichtrakool et al., Oct 2024; https://doi.org/10.1016/j.pediatrneurol.2024.06.013) (chanvanichtrakool2024unravelingthelink pages 1-3).

Additional mechanistic detail from hyperammonemia literature (relevant to UCD crises): - A 2023 review of hyperammonemic encephalopathy highlights astrocyte-localized glutamine synthetase (GS) and supports a causal role of glutamine in edema by noting that pharmacologic GS inhibition can prevent ammonia-induced astrocyte swelling/brain edema; it further links ammonia/glutamine to mitochondrial permeability dysfunction, oxidative/nitrosative stress, neurotransmission disruption, and inflammatory contributions (Lu, Feb 2023; https://doi.org/10.3390/biom13020396) (lu2023cellularpathogenesisof pages 1-2, lu2023cellularpathogenesisof pages 2-4).

Systems-level consequences (brain): - Osmotic/edema: astrocyte glutamine accumulation → swelling → cerebral edema and intracranial pressure risk (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6). - Neurotransmission/excitability: increased Glx (MRS), impaired glutamate–glutamine cycling, and excitotoxicity are implicated in seizure susceptibility (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6, lu2023cellularpathogenesisof pages 2-4). - Energy metabolism: disrupted glucose/energy metabolism during hyperammonemia is explicitly cited as a seizure mechanism in UCD crises (chanvanichtrakool2024unravelingthelink pages 1-3). - Nitric oxide pathway disruption: “impaired nitric oxide synthesis” is named as a seizure-related mechanism in UCD crises; this is especially relevant in ASL deficiency, which is associated with systemic phenotypes beyond hyperammonemia (chanvanichtrakool2024unravelingthelink pages 1-3, duff2024genetherapyfor pages 2-4).

1.3 Liver pathophysiology beyond ammonia: oxidative stress/redox and chronic liver disease (ASL deficiency exemplar)

A major 2024 mechanistic advance is a more explicit link between ASL deficiency (argininosuccinic aciduria, ASA) and hepatic glutathione dysregulation. Gurung et al. (Science Translational Medicine, Jan 2024; https://doi.org/10.1126/scitranslmed.adh1334) report dysregulated glutathione biosynthesis and upstream cysteine utilization in ASL-deficient patients and mice; cysteine metabolism is upregulated while glutathione is depleted and antioxidant pathways are downregulated (gurung2024mrnatherapycorrects pages 1-3). This provides a molecular basis for chronic liver disease manifestations in ASA beyond episodic hyperammonemia.

2. Key molecular players

2.1 Genes/proteins (causal)

Core urea-cycle and related genes explicitly enumerated in the retrieved UCD sources: - NAGS (N-acetylglutamate synthase): produces N-acetylglutamate (NAG), obligate CPS1 activator; arginine activates NAGS (fenves2025gastricbypassassociated pages 12-15, erdal2025aminoacidmetabolism pages 4-4). - CPS1 (carbamoyl phosphate synthetase 1): first mitochondrial urea-cycle step (yin2024asurvivalguide pages 16-19, meier2024noncirrhotichyperammonemiaand pages 13-16). - OTC (ornithine transcarbamylase): mitochondrial conversion of carbamoyl phosphate + ornithine → citrulline; deficiency linked to orotic acid elevation (fenves2025gastricbypassassociated pages 10-12, erdal2025aminoacidmetabolism pages 4-4). - ASS1 (argininosuccinate synthase 1) (citrullinemia type I) (yin2024asurvivalguide pages 16-19). - ASL (argininosuccinate lyase) (argininosuccinic aciduria) (yin2024asurvivalguide pages 16-19, gurung2024mrnatherapycorrects pages 1-3). - ARG1 (arginase 1) (argininemia): hydrolyzes arginine → ornithine + urea; mutations cause hyperargininemia and progressive spasticity phenotype (nteli2024argininemiapathophysiologyand pages 2-3). - SLC25A15 (ORNT1; ornithine transporter) (HHH syndrome) (yin2024asurvivalguide pages 16-19, erdal2025aminoacidmetabolism pages 4-4). - SLC25A13 (citrin; aspartate–glutamate carrier) (citrin deficiency) (yin2024asurvivalguide pages 16-19).

2.2 Chemical entities / metabolites

Core metabolites and diagnostic/effector molecules: - Ammonia (NH3/NH4+): proximal toxic effector driving neurotoxicity (yin2024asurvivalguide pages 16-19, enokizono2023neuroimagingfindingsof pages 4-6). - Glutamine: astrocytic ammonia sink/osmolyte; seizure risk biomarker during crises (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6). - Citrulline: urea-cycle intermediate; low in proximal defects; supplementation used therapeutically (yin2024asurvivalguide pages 16-19, imbard2023citrullineinthe pages 1-2). - Arginine: urea-cycle intermediate and NAGS activator; supplementation used therapeutically except in ARG1 deficiency; also implicated as major driver in ARG1-D pathophysiology (nteli2024argininemiapathophysiologyand pages 2-3, imbard2023citrullineinthe pages 10-11). - Orotic acid: elevated in OTC deficiency via carbamoyl phosphate overflow into pyrimidine pathway (fenves2025gastricbypassassociated pages 10-12, erdal2025aminoacidmetabolism pages 4-4).

Therapeutics and nitrogen scavengers: - Sodium phenylbutyrate → phenylacetate → phenylacetylglutamine: alternative nitrogen excretion; phenylacetate “conjugates with glutamine… to form phenylacetylglutamine,” renally excreted (mechanism-of-action text) (burlina2023longtermmanagementof pages 5-8). - Sodium benzoate (nitrogen scavenger) used acutely and chronically (yin2024asurvivalguide pages 16-19).

Emerging biomarker/theranostic (ASA): - [18F]FSPG PET radiotracer ((S)-4-(3-18F-fluoropropyl)-L-glutamate) used as noninvasive marker of glutathione dysregulation and treatment response in ASL deficiency (gurung2024mrnatherapycorrects pages 3-4, gurung2024mrnatherapycorrects pages 7-9, gurung2024mrnatherapycorrects pages 1-3).

2.3 Cell types (primary)

2.4 Anatomical locations

3. Dysregulated pathways and biological processes (GO-oriented)

(Representative GO-style terms; intended for knowledge-base annotation)

3.1 Biological processes

3.2 Dysregulated molecular pathways (conceptual)

4. Cellular components (GO-CC oriented)

5. Disease progression model (sequence of events)

Stage 0: genetic defect and reduced urea-cycle flux

Inherited deficiency in a urea-cycle enzyme/transporter reduces hepatic ureagenesis capacity (yin2024asurvivalguide pages 16-19).

Stage 1: trigger-driven catabolic stress

Infections, fasting, postpartum or postoperative stress, increased protein intake, and medications such as valproate can precipitate hyperammonemia in susceptible individuals, including partial/late-onset forms (meier2024noncirrhotichyperammonemiaand pages 13-16, nteli2024argininemiapathophysiologyand pages 2-3).

Stage 2: hyperammonemia and systemic metabolic derangements

Rising ammonia and related amino-acid derangements (low citrulline/arginine; high glutamine; orotic acid in OTC) emerge; compensation via glutamine synthesis can be overwhelmed (fenves2025gastricbypassassociated pages 10-12, meier2024noncirrhotichyperammonemiaand pages 13-16).

Stage 3: brain ammonia influx → astrocyte glutamine accumulation → edema and network dysfunction

Ammonia crosses BBB and is converted to glutamine; glutamine acts as osmolyte producing astrocyte swelling and cerebral edema. Neurotransmission and energy metabolism are perturbed, facilitating seizures/encephalopathy (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6).

Stage 4: clinical manifestations and outcomes

Clinical spectrum ranges from neonatal rapidly progressive encephalopathy/coma to recurrent late-onset episodes. In some UCDs (e.g., ARG1 deficiency), progressive spasticity dominates; in others, severe crises cause death or neurologic sequelae (yin2024asurvivalguide pages 16-19, nteli2024argininemiapathophysiologyand pages 2-3).

6. Phenotypic manifestations (HP-oriented) and mechanistic links

Representative phenotypes explicitly noted across retrieved sources: - Hyperammonemic encephalopathy / altered mental status / coma (ammonia neurotoxicity; edema) (yin2024asurvivalguide pages 16-19). - Seizures (including subclinical seizures): linked to severity of hyperammonemia and glutamine; mechanisms include excitotoxicity, AQP4 changes, energy metabolism disruption, NO impairment (chanvanichtrakool2024unravelingthelink pages 1-3). - Cerebral edema: glutamine osmotic effect and astrocyte swelling (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6). - Developmental delay / intellectual disability / motor impairment: prominent in specific subtypes (ASLD developmental delay/epilepsy; ARG1 spastic diplegia) (duff2024genetherapyfor pages 2-4, nteli2024argininemiapathophysiologyand pages 2-3). - Liver disease (hepatomegaly/fibrosis/chronic liver disease): noted in UCDs and mechanistically emphasized in ASL deficiency via glutathione dysregulation (gurung2024mrnatherapycorrects pages 1-3, duff2024genetherapyfor pages 2-4).

7. Recent developments (prioritizing 2023–2024)

7.1 Quantitative seizure risk modeling during UCD crises (2024)

In a UCD cohort study (Pediatric Neurology, Oct 2024; https://doi.org/10.1016/j.pediatrneurol.2024.06.013), seizures occurred in 13% of hyperammonemic events, while EEG revealed frequent occult seizures (subclinical seizures in 27% of encephalopathic crises without clinical seizures; 53% when clinical seizures were present). Biochemically, seizure odds increased 2.65-fold per 100 µmol/L ammonia and 1.14-fold per 100 µmol/L glutamine, supporting combined ammonia+glutamine risk stratification and neuromonitoring decisions (chanvanichtrakool2024unravelingthelink pages 1-3).

7.2 Neuroimaging biomarkers of hyperammonemic injury (2023)

A 2023 radiology review emphasizes ^1H-MRS patterns in UCDs: elevated lactate and Glx, and reduced myo-inositol (osmolyte buffer) correlating with severity, consistent with glutamine-driven osmotic stress biology (Enokizono et al., Feb 2023; https://doi.org/10.1007/s11604-023-01396-0) (enokizono2023neuroimagingfindingsof pages 4-6).

7.3 ASL deficiency: glutathione metabolism + PET biomarker + mRNA therapy (2024)

Gurung et al. (Science Translational Medicine, Jan 2024; https://doi.org/10.1126/scitranslmed.adh1334) provide mechanistic evidence that ASL deficiency includes a liver redox/glutathione defect and propose [18F]FSPG PET to monitor disease and response (gurung2024mrnatherapycorrects pages 1-3). Quantitatively, [18F]FSPG retention decreased from 22 ± 2.3 %ID/g (untreated) to 11 ± 2.0 %ID/g (mRNA-treated) (p=0.026), compared to 5.0 ± 2.8 %ID/g in wild-type; ureagenesis was restored (stable isotope labeling), and hepatic glutathione was restored to near WT (gurung2024mrnatherapycorrects pages 7-9).

7.4 Gene and RNA therapeutics: delivery constraints and design principles (2024)

A 2024 gene-therapy review highlights that small increases in residual enzyme activity can produce substantial clinical benefit and cites a functional threshold around ~10% activity, but notes that required hepatocyte coverage may be higher; it also emphasizes liver zonation (periportal enzyme enrichment) and the challenge of episomal-vector dilution in growing pediatric livers (Duff et al., Apr 2024; https://doi.org/10.1002/jimd.12609) (duff2024genetherapyfor pages 2-4). A 2024 RNA-therapeutics review describes hepatocyte-targeted delivery platforms (LNPs, GalNAc conjugates) and notes that mRNA approaches are transient (necessitating re-dosing) while gene editing offers “potential… permanent correction… after a single dose,” albeit with safety risks and delivery limitations (Richard et al., Oct 2024; https://doi.org/10.1002/jimd.12807) (richard2024exploringrnatherapeutics pages 1-2, richard2024exploringrnatherapeutics pages 6-7).

8. Current applications and real-world implementation

8.1 Acute hyperammonemia management thresholds and dialysis triggers

A clinical “survival guide” for UCD crises provides operational thresholds: in neonates, suspect IEM at >200 µmol/L; after neonatal period, suspect IEM at >100 µmol/L. Very poor prognosis is associated with plasma NH4+ >1000 µmol/L and prolonged coma; extracorporeal therapy is recommended when ammonia escalates to >500 µmol/L or if encephalopathic, specifying CRRT initiation (yin2024asurvivalguide pages 16-19).

8.2 Nitrogen scavengers (mechanism, dosing, monitoring)

Sodium phenylbutyrate is a nitrogen-binding agent for chronic UCD management (selected enzyme deficiencies) and is “metabolized to phenylacetate,” which “conjugates with glutamine… to form phenylacetylglutamine,” excreted by kidneys—an alternative route for waste nitrogen excretion (mechanism-of-action section) (burlina2023longtermmanagementof pages 5-8). Dosing and monitoring include weight/BSA-based daily dosing (max 20 g/day), plasma ammonia monitoring for dose adjustment, and vigilance for phenylacetate-associated neurotoxicity and hypokalemia due to phenylacetylglutamine renal loss (burlina2023longtermmanagementof pages 1-2).

8.3 Urea-cycle intermediate supplementation: citrulline vs arginine (quantitative clinical data)

A large retrospective cohort (Orphanet J Rare Dis, Jul 2023; https://doi.org/10.1186/s13023-023-02800-8) reported mean ammonia concentrations during supplementation periods of 35.9 µmol/L with citrulline, 49.8 µmol/L with arginine, and 53.0 µmol/L with arginine+citrulline; citrulline increased plasma arginine from 67.6 to 84.9 µmol/L (P<0.05) (imbard2023citrullineinthe pages 1-2). Mechanistically, citrulline “is converted to arginine through the renal pathway of arginine synthesis,” and unlike arginine, citrulline does not undergo extensive intestinal/hepatic metabolism, improving arginine bioavailability (imbard2023citrullineinthe pages 10-11).

8.4 Liver transplantation and long-term follow-up

Expert gene-therapy and bibliometric syntheses emphasize that liver transplantation is currently the only curative option for many UCDs, but carries morbidity and life-long immunosuppression, motivating gene/RNA therapy development (duff2024genetherapyfor pages 1-2, wang2025globalresearchdynamics pages 1-2).

9. Expert opinion and analysis (authoritative sources)

  • Liver-targeting rationale: Because urea-cycle enzymes are expressed in liver (periportal hepatocytes) and the liver has favorable delivery anatomy (high blood flow and fenestrated endothelium), hepatocyte-directed gene/RNA therapies are prioritized; however, zonation and the need for broad periportal correction complicate delivery optimization (Duff et al., Apr 2024; https://doi.org/10.1002/jimd.12609) (duff2024genetherapyfor pages 2-4).
  • Evidence gaps: Clinical trials are difficult because UCDs are rare and high-level evidence for many management decisions is limited; thus, expert consensus and real-world cohort analyses remain central to practice (framed in expert-opinion literature around mild UCDs and newborn screening, and reflected by reliance on retrospective data for supplementation comparisons) (duff2024genetherapyfor pages 1-2, imbard2023citrullineinthe pages 1-2).

10. Statistics and data highlights (recent)

Epidemiology

Crisis severity thresholds (practice guidance)

  • Neonate: “Healthy <110 µmol/L”; “Suspect IEM >200 µmol/L.” Post-neonatal: “Healthy <50 µmol/L”; “Suspect IEM >100 µmol/L.” Dialysis/CRRT trigger: >500 µmol/L or encephalopathy; poor prognosis at >1000 µmol/L (yin2024asurvivalguide pages 16-19).

Seizure risk quantification (2024)

  • Seizures in 13% of HA events; odds ratio 2.65 per 100 µmol/L ammonia and 1.14 per 100 µmol/L glutamine; subclinical seizure detection rates 27% and 53% depending on clinical seizure status (chanvanichtrakool2024unravelingthelink pages 1-3).

Supplementation outcomes (2023)

ASA/ASLD biomarker and treatment response (2024)

11. Knowledge-base annotation section (ontology-oriented)

11.1 Gene/protein annotations (HGNC-style)

11.2 Cell type involvement (CL-style)

11.3 Anatomical locations (UBERON-style)

11.4 Chemicals (CHEBI-style; representative)

11.5 Disrupted biological processes (GO-style)

11.6 Phenotype associations (HP-style; representative)

12. Evidence items (with URLs and publication dates; PMIDs where available)

Note on PMIDs: The retrieved excerpts predominantly include DOIs/URLs but not PubMed IDs; therefore, PMID-level citation could not be consistently provided from available context.

  1. Enokizono M. et al. Japanese Journal of Radiology — “Neuroimaging findings of inborn errors of metabolism: urea cycle disorders…” (Feb 2023). https://doi.org/10.1007/s11604-023-01396-0 (enokizono2023neuroimagingfindingsof pages 4-6)
  2. Lu K. Biomolecules — “Cellular Pathogenesis of Hepatic Encephalopathy: An Update” (Feb 2023). https://doi.org/10.3390/biom13020396 (lu2023cellularpathogenesisof pages 1-2, lu2023cellularpathogenesisof pages 2-4)
  3. Imbard A. et al. Orphanet Journal of Rare Diseases — “Citrulline in the management of patients with urea cycle disorders” (Jul 2023). https://doi.org/10.1186/s13023-023-02800-8 (imbard2023citrullineinthe pages 1-2)
  4. Duff C. et al. Journal of Inherited Metabolic Disease — “Gene therapy for urea cycle defects…” (Apr 2024). https://doi.org/10.1002/jimd.12609 (duff2024genetherapyfor pages 1-2, duff2024genetherapyfor pages 2-4)
  5. Richard E. et al. Journal of Inherited Metabolic Disease — “Exploring RNA therapeutics for urea cycle disorders” (Oct 2024). https://doi.org/10.1002/jimd.12807 (richard2024exploringrnatherapeutics pages 1-2, richard2024exploringrnatherapeutics pages 6-7)
  6. Chanvanichtrakool M. et al. Pediatric Neurology — “Unraveling the Link: Seizure Characteristics and Ammonia Levels in Urea Cycle Disorder During Hyperammonemic Crises” (Oct 2024). https://doi.org/10.1016/j.pediatrneurol.2024.06.013 (chanvanichtrakool2024unravelingthelink pages 1-3)
  7. Gurung S. et al. Science Translational Medicine — “mRNA therapy corrects defective glutathione metabolism and restores ureagenesis…” (Jan 2024). https://doi.org/10.1126/scitranslmed.adh1334 (gurung2024mrnatherapycorrects pages 7-9, gurung2024mrnatherapycorrects pages 1-3)
  8. PHEBURANE (sodium phenylbutyrate) FDA label (Revised Jun 2022) — mechanism: phenylacetate conjugates with glutamine to phenylacetylglutamine; clinical dosing and monitoring (burlina2023longtermmanagementof pages 5-8, burlina2023longtermmanagementof pages 1-2)

Limitations of this synthesis

  • MONDO ID and PMIDs were not provided in the retrieved excerpts, though DOIs/URLs and publication dates are included.
  • Some mechanistic details (e.g., oxidative/nitrosative stress pathways and BBB inflammation) are best characterized in broader hyperammonemia literature; UCD-specific texts here emphasize osmotic glutamine mechanisms, excitotoxicity, energy metabolism disruption, and nitric oxide impairment, with more detailed oxidative stress mechanisms implied via related reviews (lu2023cellularpathogenesisof pages 2-4).

References

  1. (yin2024asurvivalguide pages 16-19): LH YIN. A survival guide a survival guide. Unknown journal, 2024.

  2. (duff2024genetherapyfor pages 1-2): Claire Duff, Ian E. Alexander, and Julien Baruteau. Gene therapy for urea cycle defects: an update from historical perspectives to future prospects. Journal of Inherited Metabolic Disease, 47:50-62, Apr 2024. URL: https://doi.org/10.1002/jimd.12609, doi:10.1002/jimd.12609. This article has 27 citations and is from a peer-reviewed journal.

  3. (fenves2025gastricbypassassociated pages 12-15): Andrew Z. Fenves, Dilara Hatipoglu, John C. Robinson, and Michael M. Rothkopf. Gastric bypass associated hyperammonemia (gabha): a case study, scoping review of the literature, and proposed new pathophysiologic mechanism. Metabolites, 15:573, Aug 2025. URL: https://doi.org/10.3390/metabo15090573, doi:10.3390/metabo15090573. This article has 0 citations.

  4. (fenves2025gastricbypassassociated pages 10-12): Andrew Z. Fenves, Dilara Hatipoglu, John C. Robinson, and Michael M. Rothkopf. Gastric bypass associated hyperammonemia (gabha): a case study, scoping review of the literature, and proposed new pathophysiologic mechanism. Metabolites, 15:573, Aug 2025. URL: https://doi.org/10.3390/metabo15090573, doi:10.3390/metabo15090573. This article has 0 citations.

  5. (erdal2025aminoacidmetabolism pages 4-4): Ranya Erdal, Kıvanç Birsoy, and Gokhan Unlu. Amino acid metabolism in liver mitochondria: from homeostasis to disease. Metabolites, 15:446, Jul 2025. URL: https://doi.org/10.3390/metabo15070446, doi:10.3390/metabo15070446. This article has 1 citations.

  6. (nteli2024argininemiapathophysiologyand pages 2-3): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.

  7. (enokizono2023neuroimagingfindingsof pages 4-6): Mikako Enokizono, Noriko Aida, Akira Yagishita, Yasuhiro Nakata, Reiko Ideguchi, Ryo Kurokawa, Tatsuo Kono, Toshio Moritani, and Harushi Mori. Neuroimaging findings of inborn errors of metabolism: urea cycle disorders, aminoacidopathies, and organic acidopathies. Japanese Journal of Radiology, 41:683-702, Feb 2023. URL: https://doi.org/10.1007/s11604-023-01396-0, doi:10.1007/s11604-023-01396-0. This article has 11 citations and is from a peer-reviewed journal.

  8. (chanvanichtrakool2024unravelingthelink pages 1-3): Mongkol Chanvanichtrakool, John M. Schreiber, Wei-Liang Chen, John Barber, Anqing Zhang, Nicholas Ah Mew, Andreas Schulze, Greta Wilkening, Sandesh C.S. Nagamani, and Andrea Gropman. Unraveling the link: seizure characteristics and ammonia levels in urea cycle disorder during hyperammonemic crises. Pediatric Neurology, 159:48-55, Oct 2024. URL: https://doi.org/10.1016/j.pediatrneurol.2024.06.013, doi:10.1016/j.pediatrneurol.2024.06.013. This article has 3 citations and is from a peer-reviewed journal.

  9. (lu2023cellularpathogenesisof pages 1-2): Kaihui Lu. Cellular pathogenesis of hepatic encephalopathy: an update. Biomolecules, 13:396, Feb 2023. URL: https://doi.org/10.3390/biom13020396, doi:10.3390/biom13020396. This article has 63 citations.

  10. (lu2023cellularpathogenesisof pages 2-4): Kaihui Lu. Cellular pathogenesis of hepatic encephalopathy: an update. Biomolecules, 13:396, Feb 2023. URL: https://doi.org/10.3390/biom13020396, doi:10.3390/biom13020396. This article has 63 citations.

  11. (duff2024genetherapyfor pages 2-4): Claire Duff, Ian E. Alexander, and Julien Baruteau. Gene therapy for urea cycle defects: an update from historical perspectives to future prospects. Journal of Inherited Metabolic Disease, 47:50-62, Apr 2024. URL: https://doi.org/10.1002/jimd.12609, doi:10.1002/jimd.12609. This article has 27 citations and is from a peer-reviewed journal.

  12. (gurung2024mrnatherapycorrects pages 1-3): Sonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, Ana Luisa Gil-Martinez, Magdalena Minnion, Loukia Touramanidou, Sherry Fang, Martina Messina, Youssef Khalil, Justyna Spiewak, Abigail R. Barber, Richard S. Edwards, Patricia Lipari Pinto, Patrick F. Finn, Alex Cavedon, Summar Siddiqui, Lisa Rice, Paolo G. V. Martini, Deborah Ridout, Wendy Heywood, Ian Hargreaves, Simon Heales, Philippa B. Mills, Simon N. Waddington, Paul Gissen, Simon Eaton, Mina Ryten, Martin Feelisch, Andrea Frassetto, Timothy H. Witney, and Julien Baruteau. Mrna therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria. Science translational medicine, 16:eadh1334-eadh1334, Jan 2024. URL: https://doi.org/10.1126/scitranslmed.adh1334, doi:10.1126/scitranslmed.adh1334. This article has 31 citations and is from a highest quality peer-reviewed journal.

  13. (meier2024noncirrhotichyperammonemiaand pages 13-16): Ciselle Ayumi Meier. Non-cirrhotic hyperammonemia and adult-onset metabolic disorders: under-recognised presentation among emergency clinicians. Other, 2024. URL: https://doi.org/10.26182/fbbe-3162, doi:10.26182/fbbe-3162. This article has 0 citations.

  14. (imbard2023citrullineinthe pages 1-2): Apolline Imbard, Juliette Bouchereau, Jean-Baptiste Arnoux, Anaïs Brassier, Manuel Schiff, Claire-Marine Bérat, Clément Pontoizeau, Jean-François Benoist, Constant Josse, François Montestruc, and Pascale de Lonlay. Citrulline in the management of patients with urea cycle disorders. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02800-8, doi:10.1186/s13023-023-02800-8. This article has 14 citations and is from a peer-reviewed journal.

  15. (imbard2023citrullineinthe pages 10-11): Apolline Imbard, Juliette Bouchereau, Jean-Baptiste Arnoux, Anaïs Brassier, Manuel Schiff, Claire-Marine Bérat, Clément Pontoizeau, Jean-François Benoist, Constant Josse, François Montestruc, and Pascale de Lonlay. Citrulline in the management of patients with urea cycle disorders. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02800-8, doi:10.1186/s13023-023-02800-8. This article has 14 citations and is from a peer-reviewed journal.

  16. (burlina2023longtermmanagementof pages 5-8): Alberto Burlina, Serena Gasperini, Giancarlo la Marca, Andrea Pession, Barbara Siri, Marco Spada, Margherita Ruoppolo, and Albina Tummolo. Long-term management of patients with mild urea cycle disorders identified through the newborn screening: an expert opinion for clinical practice. Nutrients, 16:13, Dec 2023. URL: https://doi.org/10.3390/nu16010013, doi:10.3390/nu16010013. This article has 10 citations.

  17. (gurung2024mrnatherapycorrects pages 3-4): Sonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, Ana Luisa Gil-Martinez, Magdalena Minnion, Loukia Touramanidou, Sherry Fang, Martina Messina, Youssef Khalil, Justyna Spiewak, Abigail R. Barber, Richard S. Edwards, Patricia Lipari Pinto, Patrick F. Finn, Alex Cavedon, Summar Siddiqui, Lisa Rice, Paolo G. V. Martini, Deborah Ridout, Wendy Heywood, Ian Hargreaves, Simon Heales, Philippa B. Mills, Simon N. Waddington, Paul Gissen, Simon Eaton, Mina Ryten, Martin Feelisch, Andrea Frassetto, Timothy H. Witney, and Julien Baruteau. Mrna therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria. Science translational medicine, 16:eadh1334-eadh1334, Jan 2024. URL: https://doi.org/10.1126/scitranslmed.adh1334, doi:10.1126/scitranslmed.adh1334. This article has 31 citations and is from a highest quality peer-reviewed journal.

  18. (gurung2024mrnatherapycorrects pages 7-9): Sonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, Ana Luisa Gil-Martinez, Magdalena Minnion, Loukia Touramanidou, Sherry Fang, Martina Messina, Youssef Khalil, Justyna Spiewak, Abigail R. Barber, Richard S. Edwards, Patricia Lipari Pinto, Patrick F. Finn, Alex Cavedon, Summar Siddiqui, Lisa Rice, Paolo G. V. Martini, Deborah Ridout, Wendy Heywood, Ian Hargreaves, Simon Heales, Philippa B. Mills, Simon N. Waddington, Paul Gissen, Simon Eaton, Mina Ryten, Martin Feelisch, Andrea Frassetto, Timothy H. Witney, and Julien Baruteau. Mrna therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria. Science translational medicine, 16:eadh1334-eadh1334, Jan 2024. URL: https://doi.org/10.1126/scitranslmed.adh1334, doi:10.1126/scitranslmed.adh1334. This article has 31 citations and is from a highest quality peer-reviewed journal.

  19. (chanvanichtrakool2024unravelingthelink pages 9-12): Mongkol Chanvanichtrakool, John M. Schreiber, Wei-Liang Chen, John Barber, Anqing Zhang, Nicholas Ah Mew, Andreas Schulze, Greta Wilkening, Sandesh C.S. Nagamani, and Andrea Gropman. Unraveling the link: seizure characteristics and ammonia levels in urea cycle disorder during hyperammonemic crises. Pediatric Neurology, 159:48-55, Oct 2024. URL: https://doi.org/10.1016/j.pediatrneurol.2024.06.013, doi:10.1016/j.pediatrneurol.2024.06.013. This article has 3 citations and is from a peer-reviewed journal.

  20. (richard2024exploringrnatherapeutics pages 1-2): Eva Richard, Ainhoa Martínez‐Pizarro, and Lourdes R. Desviat. Exploring rna therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease, 47:1269-1277, Oct 2024. URL: https://doi.org/10.1002/jimd.12807, doi:10.1002/jimd.12807. This article has 4 citations and is from a peer-reviewed journal.

  21. (richard2024exploringrnatherapeutics pages 6-7): Eva Richard, Ainhoa Martínez‐Pizarro, and Lourdes R. Desviat. Exploring rna therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease, 47:1269-1277, Oct 2024. URL: https://doi.org/10.1002/jimd.12807, doi:10.1002/jimd.12807. This article has 4 citations and is from a peer-reviewed journal.

  22. (burlina2023longtermmanagementof pages 1-2): Alberto Burlina, Serena Gasperini, Giancarlo la Marca, Andrea Pession, Barbara Siri, Marco Spada, Margherita Ruoppolo, and Albina Tummolo. Long-term management of patients with mild urea cycle disorders identified through the newborn screening: an expert opinion for clinical practice. Nutrients, 16:13, Dec 2023. URL: https://doi.org/10.3390/nu16010013, doi:10.3390/nu16010013. This article has 10 citations.

  23. (wang2025globalresearchdynamics pages 1-2): Yan Wang, Xueer Wang, Huiqin Zhang, and Binhui Zhu. Global research dynamics in urea cycle disorders: a bibliometric study highlighting key players and future directions. Orphanet Journal of Rare Diseases, Mar 2025. URL: https://doi.org/10.1186/s13023-025-03625-3, doi:10.1186/s13023-025-03625-3. This article has 2 citations and is from a peer-reviewed journal.